Close Menu

NEW YORK – Abbott announced after the close of the market on Wednesday that its molecular test for SARS-CoV-2 has received Emergency Use Authorization from the US Food and Drug Administration.

The Abbott RealTime SARS-CoV-2 EUA test runs on the company's PCR-based m2000 RealTime System. The company said it would work with health systems and government authorities to distribute additional instruments where needed. Right now, there are more than 175 PCR m2000 instruments in the US, each one able to run up to 470 tests in 24 hours. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bloomberg reports the US Centers for Medicare & Medicaid Services sent Orig3n a letter saying it has not corrected lab issues uncovered in an earlier inspection.

In an editorial at BMJ Opinion, two genetic counselors call for an increased focus on post-test patient care.

A new survey finds people in the US are getting their COVID-19 test results back faster, but not fast enough to help some viral control measures, NPR reports.

In PLOS this week: genomic analysis of malaria parasites in Ethiopia, loci linked to childhood BMI, and more.